The Pharmacy and Poisons Board (PPB) has mandated the recall of Tamedol oral solution (Paracetamol oral solution, 120mg/5ml, 60 mls) manufactured by Biopharma LTD, Kenya, due to quality concerns.

The recall follows multiple market complaints about the quality of several batches of the product.

The PPB confirmed that the product failed to meet the prescribed market authorization requirements.

Taking the findings into consideration, the PPB advises all pharmaceutical outlets, healthcare facilities, healthcare professionals and members of the public to take immediate action:

Quarantine the Product: STOP all further distribution, sale, issuing or use of Tamedol oral solution.

Read More

  1. COMESA issues advisory on counterfeit breast cancer drug circulating in Kenya
  2. Why PPB has issued a public warning against Benylin paediatric cough syrup
  3. Pharmacy board warns against use of suspicious ‘Asali ya Wazee’ and Truvada batches

Product Returns: Members of public are urged to return the product to their nearest healthcare facility, while healthcare facilities are instructed to return the products to their respective suppliers.

The PPB encourages the public to remain vigilant at all times and promptly report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board.

"We encourage the public to remain vigilant at all times and promptly report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board through the available charges," PPB said.

The PPB assures the public that they have implemented rigorous measures to guarantee that medicines supplied to the Kenyan market adhere to the requisite standards of quality, safety and efficacy.